NEWS
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors
Kronos Bio (Nasdaq: KRON) will present preclinical data on its p300 KAT inhibitor program for HPV-driven tumors at the EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 23-25, 2024. The company's p300 KAT inhibitor, KB-9558, shows promise in targeting HPV-driven cancers by selectively inhibiting viral oncoproteins E6 and E7.
Key findings include:
HPV-16 virus hijacks the host transcriptional cofactor p300 to drive expression of E6 and E7 oncogenes
Inhibition of p300 KAT activity downregulates E6 and E7, reactivating the tumor suppressor p53
KB-9558 demonstrates high selectivity against HPV oncoproteins
The poster presentation, scheduled for October 24, 2024, will showcase these results, potentially offering new targeted therapies for the estimated 38,000 new cases of HPV-driven cancers annually in the United States.
Key findings include:
HPV-16 virus hijacks the host transcriptional cofactor p300 to drive expression of E6 and E7 oncogenes
Inhibition of p300 KAT activity downregulates E6 and E7, reactivating the tumor suppressor p53
KB-9558 demonstrates high selectivity against HPV oncoproteins
The poster presentation, scheduled for October 24, 2024, will showcase these results, potentially offering new targeted therapies for the estimated 38,000 new cases of HPV-driven cancers annually in the United States.
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論
